Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Reply

N Engl J Med. 2025 Mar 13;392(11):1142. doi: 10.1056/NEJMc2416491.

Authors

Peter Schmid¹, Xuan Zhou², Rebecca Dent³

Affiliations

¹ Queen Mary University of London, London.
² Merck, Rahway, NJ.
³ National Cancer Center Singapore, Singapore.

PMID: 40073319
DOI: 10.1056/NEJMc2416491

No abstract available

Publication types

Letter
Comment